Stocks of Biohaven Pharmaceutical - Current price, Where to buy? Chart
| Detail | Data |
|---|---|
| Stocks: | Biohaven Pharmaceutical |
| ompany Name: | Biohaven Ltd. |
| Ticker: | BHVN |
| Exchange: | NYSE |
| Outstanding stocks: | 81,661,504 |
| 24-hour Volume: | 574,891 |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Number of Employees: | 239 |
| Country: | United States |
| City: | New Haven |
| Address: | 215 Church Street |
| P/E Ratio: | Forward P/E | EPS: | Forward EPS | Book value per share | Market capitalization |
|---|---|---|---|---|---|
| / | -8.83 | -5.73 USD | -5.95 USD | 5.28 USD | 4,288,862,208.00 USD |
| P/E Ratio: | / |
|---|---|
| Forward P/E: | -8.83 |
| EPS: | -5.73 USD |
| Forward EPS: | -5.95 |
| Book value per share: | 5.28 USD |
| Market capitalization: | 4,288,862,208.00 USD |
Biohaven Pharmaceutical
Fundamental Indicators
| Indicator | Data |
|---|---|
| Total Revenue: | / |
| Net Income: | -408,168,000.00 USD |
| Price-to-Book (P/B) Ratio: | 9.95 |
| PEG Ratio: | / |
Note: The data is approximate, subject to change over time, and may not be current; however, we strive for the highest possible accuracy.
Analysts' predictions
| Analysts | Recommendation |
|---|---|
| Issued Recommendation: | According to our data, the recommendation issued for Biohaven Pharmaceutical stocks is: buy |
| Number of Analysts: | 8 |
| Highest Target Price: | 66 USD |
| Lowest Target Price: | 55 USD |
| Average Target Price: | 59 USD |
Note: The data is approximate. Recommendations and price forecasts for Biohaven Pharmaceutical stocks based on analysts' ratings may change over time. Some recommendations may already be outdated and may not be accurate. We strongly advise against buying and selling stocks based on analysts' recommendations!
Dividend
| Dividends | Value |
|---|---|
| Dividend Amount | According to our data, the company Biohaven Pharmaceutical is currently not paying dividends. |
| Annual Yield %: | - |
| Ex-dividend Date: | - |
| Average % Yield for 5 Years: | - |
| Payout Ratio: | - |
| Value of Last Dividend Paid: | - |
| Date of Last Dividend: | - |
The dividend is displayed for the entire calendar year, however, it is usually paid out quarterly in parts. Data may change!
Where to Buy Biohaven Pharmaceutical Stocks?
If you're interested in investing in Biohaven Pharmaceutical stocks and believe in their future growth, you can purchase them through stock brokers like XTB or eToro. To make buying easier, we've prepared a table with offers from these brokers, including quick purchase of Biohaven Pharmaceutical stocks through mobile apps with client support. In this table, you can compare brokers offering real Biohaven Pharmaceutical stocks. Brokers providing the option to buy real stocks (not CFDs) are identified by "Real Stocks" in the comparison table column.
| Broker | Platforms | Regulation | Min. Deposit | Deposits / Withdrawals | CopyTrader | Real Stocks | Website Link |
|---|---|---|---|---|---|---|---|
 |
Proprietary platform, social network + CopyTrader™ | 100 USD | Bank transfer, credit cards, Skrill, PayPal, Neteller |
 Go to eToro
|
|||
 |
xStation, mobile version | 10 USD | Credit cards, Skrill, bank transfer |
 Go to XTB
|
|
|
| xStation, mobile version | Proprietary platform, social network + CopyTrader™ |
|
Go to XTB
|
Go to eToro
|
More Information about Biohaven Pharmaceutical (BHVN)
Revenues of 0.00 USD indicate room for growth and improvement for Biohaven Pharmaceutical. This presents an opportunity for further development. Negative EBITDA of -429,139,008.00 USD may indicate challenges but also opportunities for Biohaven Pharmaceutical to invest in future growth. Debt-to-equity ratio of 0.07 suggests that Biohaven Pharmaceutical has a healthy financial structure and effectively manages its debts. This is key to stable growth. Gross margin of 0.00% indicates room for Biohaven Pharmaceutical to improve cost efficiency and competitiveness. Lower profit margin of 0.00% suggests opportunities for Biohaven Pharmaceutical to increase efficiency and reduce costs.
| Indicator | Value |
|---|---|
| Revenue, Debt, and Cash Flow | |
| Company Revenue: | / |
| EBITDA: | -429,139,008.00 USD - Negative EBITDA may signal financial challenges or growth investments. |
| Earnings Per Share: | -5.73 USD |
| Book Value Per Share: | 5.28 USD |
| Total Cash: | 381,819,008.00 USD |
| Total Cash per Share: | 4.68 USD |
| Total Debt: | 30,877,000.00 USD |
| Debt to Equity Ratio: | 0.07 |
| Quick Ratio: | 7.14 |
| Current Ratio: | 7.98 |
| Free Cash Flow: | -213,767,872.00 USD |
| Operating Cash Flow: | -331,724,992.00 USD |
| Company Margins | |
| Gross Margins: | / |
| EBITDA Margins: | / |
| Operating Margins: | / |
| Profit Margins: | / |
| Performance | |
| Return on Assets: | -46.4 % |
| Return on Equity: | -84.4 % |
| Earnings Growth (1 year): | / |
| Revenue Growth (1 year): | / |
| Year-over-Year Quarterly Earnings Growth: | / |
| Valuation | |
| Market Capitalization: | 4,288,862,208.00 USD |
| Enterprise Value: | 3,933,635,072.00 USD |
| EV/Revenue: | / |
| EV/EBITDA: | -9.166 |
| Number of Shares and Short Shares | |
| Float Shares: | 65,854,570 shares |
| Shares Outstanding: | 81,661,504 shares |
| Held Percent Insiders: | 0.14 % |
| Held Percent Institutions: | 89.95 % |
| Shares Short: | 8,630,093 |
| Shares Short Prior Month: | 6,388,407 |
| Date Short Interest: | 2024-03-15 |
| Shares Percent Shares Out: | 10.57 % |
| Short Ratio: | 5.95 |
| Beta: | / |
| Short Percent of Float: | 12.23 % |
| Předpokládaný počet akcií: | 81,661,504 |
Frequently Asked Questions (FAQ)
According to our data, Biohaven Pharmaceutical does not currently pay dividends, even in 2024.
Biohaven Pharmaceutical shares are traded on the stock exchange NYSE under the ticker symbol: BHVN. You can buy or trade them with a variety of stock brokers offering real stock trading services.
According to our data, there is a buy recommendation issued for Biohaven Pharmaceutical shares by a total of 8 analysts. The average target price prediction is 59 USD per share.
The total number of Biohaven Pharmaceutical shares on the exchange is 81,661,504.00, which, at the current market capitalization, values the company at 4,288,862,208.00 USD.
